

Animal name: White faced saki (*Pithecia pithecia*)

Fact Sheet Compiled by: Tai Strike & Yedra Feltrer

Last Updated: June 2016

Fact Sheet Reviewed by: Cheryl Asa & Sally Bouteille

We would like to encourage all institutions using contraception in their animals to assess the health of their animals during and after contraception. This can be done through behavioural and endocrine monitoring, as well as through reproductive tract exams. Please contact EGZAC for advice on this.

Contraceptive methods	GnRH agonist (implant)	GnRH agonist (injection)	Progestagen (implants)	Progestagen (implant)	Progestagen (injection)	Progestagen (injection)	Surgical/Permanent
Contraceptive Product:	Deslorelin acetate	Luprolide acetate	Etonogestrel 68 mg	Levonorgestrel 2x 75mg	medroxyprogesterone acetate;	progesterone 100mg/ml	
Commercial Name:	Suprelorin ®	Lupron ®	Implanon® Nexplanon®	Jadelle®	Depo-Provera®, Depo-Provera®	Delvosteron®	
Product Availability:	4.7mg ('Suprelorin 6') and 9.4 mg ('Suprelorin 12') widely available through veterinary drug distributors in the EU.	Luprolide acetate licenced for human use	Manufactured by Bayer Schering Pharma AG. Available through human drug distributors	Manufactured by Organon. Available through human drug distributors	Manufactured by Pfizer. Widely available throughout Europe through human drug distributors.	Manufactured by MSD animal Health UK, Intervet Europe. Licensed for use in female dogs, cats, and ferrets; available through veterinary distributors.	N/A
Restrictions and/or permit required by Importing Country:	EGZAC recommends: always check with your local licencing authority	Data deficient	EGZAC recommends: always check with your local licencing authority	EGZAC recommends: always check with your local licencing authority	EGZAC recommends: always check with your local licencing authority	EGZAC recommends: always check with your local licencing authority	N/A
Mechanism of action:	GnRH agonist suppress the reproductive endocrine system, preventing production of pituitary and gonadal hormones. As an agonist of the GnRH initially stimulates the reproductive system -which can result in oestrus and ovulation in females or temporary enhancement of testosterone and spermatogenesis in males- therefore additional contraception needed during this time. Please see below and refer to Deslorelin datasheet for detailed information	GnRH agonist suppress the reproductive endocrine system, preventing production of pituitary and gonadal hormones	Interference with fertilization by thickening cervical mucus, interrupting gamete transport, disruption of implantation, inhibition of LH surge necessary for ovulation	Interference with fertilization by thickening cervical mucus, interrupting gamete transport, disruption of implantation, inhibition of LH surge necessary for ovulation	Anti-estrogenic activity. Interference with fertilization by thickening cervical mucus, interrupting gamete transport, disruption of implantation, inhibition of LH surge necessary for ovulation	Anti-estrogenic activity. Interference with fertilization by thickening cervical mucus, interrupting gamete transport, disruption of implantation, inhibition of LH surge necessary for ovulation	Vasectomy recommended Permanent contraception by surgical gonadectomy; likely side effects include weight gain, loss of secondary sex characteristics
Insertion/Placement:	Sub-cutaneous, in a place where it can be easily detected or seen for removal at a later date (i.e. upper inner arm); refer Suprelorin fact sheet for effective method of implant placement (tunnellisation)	Injectable	Intramuscular or subcutaneous. EGZAC recommends sub-cutaneous, upper inner arm for visibility (aid for later removal)	Intramuscular or subcutaneous. EGZAC recommends sub-cutaneous, upper inner arm for visibility (aid for later removal)	Injectable intramuscular	Injectable subcutaneously - do not inject intradermally or into subcutaneous fat or scar tissue	Surgical
Females		Data deficient					
Dose	Dosages and duration of efficacy have not been well established for primate species. Our records suggest 1 x 4.7 mg for a minimum duration of 6 months or 1 x 9.4 mg for a minimum duration of 12 months. DO NOT CUT IMPLANT. Please contact EGZAC for specific dosage instructions.	Dosing information is not available; extrapolation from human literature is likely the best place to start. Please contact EGZAC for specific dosage instructions.	Our records suggest 1/4 to 1/2 rod, depending on weight. Please contact EGZAC advisory panel for specific dosage instructions. Doses not well established	Recommended 1to 2 rods, depending on weight. Please contact EGZAC for specific dosage instructions. Doses not well established	MPA can have a variable length of duration and a much higher dose is needed than in Old World primates for efficacy: 20mg/kg body wt of Depo-Provera, effective for approximately 30 days. For these reasons MPA is only advisable as a short term contraceptive to suppress post-partum oestrus.	A dose of 50 mg/kg of Delvosteron has been used in a collection for short term contraception being effective for approximately 3 months. This drug is only advisable as a short term contraceptive eg to suppress post-partum oestrus, introduction of newly vasectomised male . Repeated use not advised.	N/A
Latency to effectiveness:	3 weeks average - additional contraception needed during this time (PLEASE see product data sheet). In cebids 5mg Megestrol acetate pills daily 7 days before and 7 days after implant has been used	Same as deslorelin with an initial stimulation phase and suppression should then occur 3-4 weeks later (please refer to deslorelin and lupron datasheet for more details).	In general inhibition of ovulation after 1 day when inserted on day 1-5 of cycle or when replacing oral progestogen. As the right stage during menstrual cycle is often unknown, it is advised to use other contraceptive methods for at least 7-14 days after insertion of the implant depending on administration route (Im or SC)	In general inhibition of ovulation after 1 day when inserted on day 1-5 of cycle or when replacing oral progestogen. As the right stage during menstrual cycle is often unknown, it is advised to use other contraceptive methods for at least 7-14 days after insertion of the implant depending on administration route (Im or SC)	1-3 days post injection. However, if the cycle stage is not known then extra time must be allowed; therefore, separation of the sexes or alternative contraception should be used for at least 1 week. • Depo-Provera injection can be used to prevent the post-partum oestrus until a suitable longer term implant can be placed or as longer term contraception.	1-3 days post injection. However, if the cycle stage is not known then extra time must be allowed; therefore, separation of the sexes or alternative contraception should be used for at least 1 week. • Depo-Provera injection can be used to prevent the post-partum oestrus until a suitable longer term implant can be placed or as longer term contraception.	N/A
Oestrus cycles during contraceptive treatment:	Initial oestrus and ovulation (during the 3 weeks of stimulation) then no oestrus cycle. To suppress the initial oestrus and ovulation you can follow the megestrol acetate protocol mentioned above.	Same as deslorelin.	Oestrus is inhibited. Menstruation in non-human primates are more or less present with regular cyclicity. This is an individual and dose-dependent response.	Oestrus is inhibited. Menstruation in non-human primates are more or less present with regular cyclicity. This is an individual and dose-dependent response.	Oestrus behaviour may be observed. Ovulation and cycling can occur in adequately contracepted individuals (but is unlikely and the degree of suppression is dose dependent).	Oestrus behaviour may be observed. Ovulation and cycling can occur in adequately contracepted individuals (but is unlikely and the degree of suppression is dose dependent).	N/A

Use during pregnancy:	Not recommended	Not recommended	In non-human primates progestagens normally do not interfere with parturition. However in other species progestagens are not recommended for use in pregnant animals because of the risk of prolonged gestation, stillbirth or abortion.	In non-human primates progestagens normally do not interfere with parturition. However in other species progestagens are not recommended for use in pregnant animals because of the risk of prolonged gestation, stillbirth or abortion.	Progestagens are not recommended in pregnant animals because of the possibility of prolonged gestation, stillbirth, abortion, etc. In some species, although the effect may depend on dose. Progestagens in late pregnancy seem not to interfere with parturition in primates, but this is a taxon-specific phenomenon.	Progestagens are not recommended in pregnant animals because of the possibility of prolonged gestation, stillbirth, abortion, etc. In some species, although the effect may depend on dose. Progestagens in late pregnancy seem not to interfere with parturition in primates, but this is a taxon-specific phenomenon.	N/A
Use during lactation:	No contraindications once lactation established	No contraindications once lactation established	Considered safe for nursing infant.	Considered safe for nursing infant.	Considered safe for nursing infant.	Considered safe for nursing infant.	N/A
Use in prepubertals or juveniles:	Data deficient in this group, see product information sheet	Data deficient in this group, see product information sheet	The use of synthetic progestagens in pre-pubertals or juveniles has not been fully assessed. Possible long-term effects on fertility are not known.	The use of synthetic progestagens in pre-pubertals or juveniles has not been fully assessed. Possible long-term effects on fertility are not known.	The use of synthetic progestagens in pre-pubertals or juveniles has not been fully assessed. Possible long-term effects on fertility are not known.	The use of synthetic progestagens in pre-pubertals or juveniles has not been fully assessed. Possible long-term effects on fertility are not known.	N/A
Use in seasonal breeders:	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Duration	Duration of efficacy has not been well established. As a guide: 4.7 mg implants will suppress for a MINIMUM of 6 months; 9.4mg will be effective for a MINIMUM of 12 months.	Not well established, duration of effect being likely related to the dose. Higher doses result in longer duration of effect. This is extremely data deficient	2.5-3 years in various primates	2-3 years in various primates	Dose dependant: 30 days in general. However, effects could last 1-2 years in some individuals.	Dose dependant: 30-90 days in general. However, effects could last 1-2 years in some individuals.	N/A
Reversibility	Considered reversible but every species has not been tested. Duration to reversibility extremely variable. Removal of implant to aid reversibility is recommended.	Considered reversible but every species has not been tested. duration to reversibility extremely variable.	Designed to be fully reversible but individual variations can occur. To increase potential for full reversibility implants must be removed. We currently hold 1 record of reversal for the species within 6 months of implant removal.	Designed to be fully reversible but individual variations can occur. To increase potential for full reversibility implants must be removed. We have one record of a reversal within one year of implant removal.	Designed to be fully reversible but individual variations can occur. We hold 1 record of a reversal in this species, where young were born 3 years after her final injection.	Designed to be fully reversible but individual variations can occur	N/A
Effects on Behaviour	None observed except lack of libido. There are anecdotal reports of change of hierarchy with the behavioural implications that this may have.	Same as deslorelin	Effects on behaviour have not been studied, every individual may react differently. Because progestagens can suppress ovulation it can be expected that courtship and mating behaviour will be affected in some way. Further research in the subject is necessary.	Effects on behaviour have not been studied, every individual may react differently. Because progestagens can suppress ovulation it can be expected that courtship and mating behaviour will be affected in some way. At high doses can have masculinising effect. Further research in the subject is necessary.	Effects on behaviour have not been studied, every individual may react differently. Because it binds readily to androgen receptors and is antiestrogenic, females may experience male-like qualities (increased aggression, development of male secondary sex characteristics, etc.) Further research in the subject is necessary.	Effects on behaviour have not been studied, every individual may react differently. Because it binds readily to androgen receptors and is antiestrogenic, females may experience male-like qualities (increased aggression, development of male secondary sex characteristics, etc.) Further research in the subject is necessary.	N/A
Effects on sexual physical characteristics	Similar to gonadectomy.	Some dichromatic species may change colour.	Some signs of oestrus behaviour might occur. Ovulation may also occur even though pregnancy does not ensue.	Some signs of oestrus behaviour might occur. Ovulation may also occur even though pregnancy does not ensue.	See above	See above	N/A
Males	Data deficient	Data deficient	Not recommended	Not recommended	Not recommended	Not recommended	Vasectomy
Dose	Our data suggests that 1x implants are sufficient. As a guide, 1x 4.7mg implants for a minimum duration of 6 months, and 1x 9.4mg implant for a minimum duration of 12 months. Data deficient. Please contact EGZAC for specific dosage instructions.	Usually a higher dose than in females are required in males. Data deficient. Please contact EGZAC for specific dosage instructions.	N/A	N/A	N/A	N/A	N/A
Latency to effectiveness:	Depending on the species there may be fertile sperm present in vas deferens for 6-8 weeks post treatment or even longer. Testosterone decreases after 3-4 weeks but sperm can stay fertile for many weeks after. Additional contraception needed during this time or separation of the sexes.	Depending on the species there may be fertile sperm present in vas deferens for 6-8 weeks post treatment or even longer. Testosterone decreases after 3-4 weeks but sperm can stay fertile for many weeks after. Additional contraception needed during this time or separation of the sexes	N/A	N/A	N/A	N/A	Depending on species and individual, perhaps as long as 2 months or more
Use in prepubertals or juveniles:	Data deficient in this group, see product information sheet	Data deficient in this group, see product information sheet	N/A	N/A	N/A	N/A	Data deficient
Use in seasonal breeders:	N/A	N/A	N/A	N/A	N/A	N/A	

Duration and Reversibility	No data yet but deslorelin is considered reversible. Data deficient in this group, see product information sheet.	No data yet but lupron is considered reversible. Data deficient in this group, see product information sheet.	N/A	N/A	N/A	N/A	The procedure should not be used in males likely to be recommended for subsequent breeding as reversal is unlikely
Effects on Behaviour	Testosterone related aggression is likely to decrease. Data deficient in this group, see product information sheet.	Testosterone related aggression is likely to decrease. Data deficient in this group, see product information sheet.	N/A	N/A	N/A	N/A	Vasectomy will not affect androgen-dependent behaviours
Effects on sexual physical characteristics	Some dichromatic species may change colour if testosterone related. Decrease in body size, feminisation of males.	Some dichromatic species may change colour if testosterone related. Decrease in body size, feminisation of males.	N/A	N/A	N/A	N/A	None observed in non-human primates
General:							
Side effects	Similar to gonadectomy; especially weight gain	Similar to gonadectomy; especially weight gain	Possible weight gain, possible increased or decreased frequency of bleeding during menstruation. EGZAC recommends always reading the manufacturer's data sheet	Possible weight gain, possible increased or decreased frequency of bleeding during menstruation. At high doses can have masculinising effect. EGZAC recommends always reading the manufacturer's data sheet	Long term use is not recommended since it can have possible deleterious effects on the uterus and mammary tissue. Progestins are likely to cause weight gain in all species. In the human literature, Depo-Provera® has been linked to mood changes. Because it binds readily to androgen receptors and is anti-estrogenic, females may experience male-like qualities (increased aggression, development of male secondary sex characteristics, etc.) EGZAC recommends always reading the manufacturer's data sheet.	Long term use is not recommended since it can have possible deleterious effects on the uterus and mammary tissue. Progestins are likely to cause weight gain in all species. In the human literature, progestagens has been linked to mood changes. Because it binds readily to androgen receptors and is anti-estrogenic, females may experience male-like qualities (increased aggression, development of male secondary sex characteristics, etc.) In some diabetic animals Delvosteron has led to an increased insulin requirement, it is advised that the product be used with caution in diabetic animals and that urine glucose levels are carefully monitored during the month after dosing. EGZAC recommends always reading the manufacturer's data sheet.	N/A
Warnings	Causes initial gonadal stimulation; correct administration essential - see product information sheet	Causes initial gonadal stimulation	Interaction with other drugs are known to occur and may influence protection against pregnancy. In some diabetic animals progestagens has led to an increased insulin requirement, it is advised that the product be used with caution in diabetic animals and that urine glucose levels are carefully monitored during the month after dosing. EGZAC recommends always reading the manufacturer's data sheet.	Interaction with other drugs are known to occur and may influence protection against pregnancy. In some diabetic animals progestagens has led to an increased insulin requirement, it is advised that the product be used with caution in diabetic animals and that urine glucose levels are carefully monitored during the month after dosing. EGZAC recommends always reading the manufacturer's data sheet.	Interaction with other drugs are known to occur and may influence protection against pregnancy. In some diabetic animals progestagens has led to an increased insulin requirement, it is advised that the product be used with caution in diabetic animals and that urine glucose levels are carefully monitored during the month after dosing. EGZAC recommends always reading the manufacturer's data sheet.	Interaction with other drugs are known to occur and may influence protection against pregnancy EGZAC recommends always reading the manufacturer's data sheet.	Infection of the surgical wound might occur. Intradermal closure of the skin is advised together with prophylactic antibiotic treatment and NSAID

Reporting Requirements: In order to increase our knowledge of the efficacy of contraception methods in *Pithecia sp.* it is recommended that all individuals on contraception be reported to EGZAC

References:

- 1) Wildlife Contraception: Issues, Methods, and Applications. Edited by Cheryl S. Asa and Ingrid J. Porton. 2005. The John Hopkins University Press.
- 2) Noah Compendium of data sheets - Delvosteron - <http://www.noahcompendium.co.uk>

Disclaimer: EGZAC endeavours to provide correct and current information on contraception from various sources. As these are prescription only medicines it is the responsibility of the veterinarian to determine the dosage and best treatment for an individual